靶向CD19阴性逃逸的CD19/20/22CAR-T细胞
靶向CD19的CAR-T治疗B系急性淋巴细胞白血病后,高达39%的患者出现CD19阴性复发。研究发现CD19阴性逃逸伴随CD20和CD22表达下调但保留可靶向性。通过三顺反子转基因共表达三种CAR分子,CD19/20/22CAR-T细胞在体外和动物模型中能杀伤CD19阴性白血病细胞,且对CD19阳性病效果与CD19CAR-T相当。
要点
- CD19阴性复发与CD20/CD22表达下调但保留靶向性相关
- CD19/20/22CAR-T细胞可杀伤CD19阴性逃逸的白血病细胞
- 对CD19阳性白血病疗效与CD19CAR-T细胞相当
核心结论
- CD19/20/22CAR-T细胞不依赖CD19表达,可作为难治性B系急性淋巴细胞白血病的挽救性或一线CAR治疗。
研究设计与样本
- 研究构建了共表达CD19、CD20和CD22 CAR分子的CD19/20/22CAR-T细胞,并在体外和动物模型中评估其对CD19阴性原代白血病细胞的杀伤效果。
主要发现
- 靶向CD19的CAR-T治疗后,高达39%的患者以CD19阴性疾病复发;CD19阴性逃逸与CD20和CD22表达下调但保留可靶向表达相关。
- CD19/20/22CAR-T细胞在体外和动物模型中杀伤CD19CAR-T治疗后复发患者的CD19阴性原始细胞以及CRISPR/Cas9 CD19敲除的原代B系急性淋巴细胞白血病细胞,而CD19CAR-T细胞无效。
- CD19/20/22CAR-T细胞与靶细胞形成致密免疫突触,介导有效的溶细胞复合物形成,在单细胞追踪研究中是高效的连续杀伤细胞,且对原代CD19阳性疾病的疗效与CD19CAR-T细胞相当。
临床怎么用
- 对于CD19CAR-T治疗后CD19阴性复发的B系急性淋巴细胞白血病患者,CD19/20/22CAR-T细胞可能作为挽救性治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(-) disease. We report that CD19(-) escape is associated with downregulation, but preservation, of targetable expression of CD20 and CD22. Accordingly, we reasoned that broadening the spectrum of CD19CAR T-cells to include both CD20 and CD22 would enable them to target CD19(-) escape BL-ALL while preserving their upfront efficacy. We created a CD19/20/22-targeting CAR T-cell by coexpressing individual CAR molecules on a single T-cell using one tricistronic transgene. CD19/20/22CAR T-cells killed CD19(-) blasts from patients who relapsed after CD19CAR T-cell therapy and CRISPR/Cas9 CD19 knockout primary BL-ALL both in vitro and in an animal model, while CD19CAR T-cells were ineffective. At the subcellular level, CD19/20/22CAR T-cells formed dense immune synapses with target cells that mediated effective cytolytic complex formation, were efficient serial killers in single-cell tracking studies, and were as efficacious as CD19CAR T-cells against primary CD19(+) disease. In conclusion, independent of CD19 expression, CD19/20/22CAR T-cells could be used as salvage or front-line CAR therapy for patients with recalcitrant disease.
引用
- Fousek K, Watanabe J, Joseph SK, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2020. PMID: 32205861. doi:10.1038/s41375-020-0792-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。